Supplementary Tables 1-4 from Phase I Study of Pazopanib in Patients with Advanced Solid Tumors and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study
Year: 2023
Type: supplementary-materials
Abstract: PDF - 90K, Supplemental Table 1: Most Frequently Reported Adverse Events at Least Possibly Related to Pazopanib Supplemental Table 2: Steady-State Pazopanib Metabolite Pharmacokinetics Measured in All Patients at Week 3 (medians and ranges) Supplemental Table 3: Ratio of Metabolite AUC(0-6) to Pazopanib AUC(0-6) Measured at Steady-State in All Patients at Week 3 (medians and ranges) Supplemental Table 4: First-dose Pazopanib Metabolite Pharmacokinetics in Expanded Cohorts and the Maximum Tolerated Dose (medians and ranges)
Authors: Stephen I. Shibata, Vincent Chung, Timothy W. Synold, Jeffrey A. Longmate, A. Benjamin Suttle, Lone H. Ottesen, Heinz-Josef Lenz, Shivaani Kummar, R. Donald Harvey, Anne L. Hamilton, Bert H. O'Neil, John Sarantopoulos, Patricia LoRusso, Michelle A. Rudek, Afshin Dowlati, Daniel L. Mulkerin, Chandra P. Belani, Leena Gandhi, S. Cecilia Lau, S. Percy Ivy, Edward M. Newman
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: gold
OpenAlex ID: W4361909126